Dalbavancin as a second-line treatment in methicillin-resistant Staphylococcus aureus prosthetic vascular graft infection

Infection. 2020 Apr;48(2):309-310. doi: 10.1007/s15010-019-01379-2. Epub 2019 Nov 29.

Authors

Arturo Ciccullo¹, Gabriele Giuliano², Francesco Vladimiro Segala², Eleonora Taddei², Damiano Farinacci², Federico Pallavicini^{2

3}

Affiliations

¹ Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy. [email protected].
² Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy.
³ Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC Malattie Infettive, Rome, Italy.

PMID: 31784895
DOI: 10.1007/s15010-019-01379-2

No abstract available

Publication types

Letter
Comment

MeSH terms

Humans
Methicillin
Methicillin-Resistant Staphylococcus aureus*
Soft Tissue Infections*
Teicoplanin / analogs & derivatives

Substances

Teicoplanin
dalbavancin
Methicillin